EMEA-002448-PIP01-18-M02 - paediatric investigation plan
PEGylated-fibroblast growth factor 21 (BMS-986036)
PIPHuman
Bristol-Myers Squibb International Corporation
Tel. +44 1895523740
E-mail: medical.information@bms.com
P/0346/2021 : EMA decision of 18 August 2021 on the acceptance of a modification of an agreed paediatric investigation plan for pegylated-fibroblast growth factor 21 (BMS-986036) (EMEA-002488-PIP01-18-M02)